Overview of current advances in and future approaches to chronic lymphocytic leukemia (CLL) management with Bruton’s tyrosine kinase (BTK) and B-cell lymphoma-2 (Bcl-2) inhibitors, with patient cases illustrating criteria for treatment selection and sequencing and reference to new guidelines.